-

Rion to Present at the 42nd Annual J.P. Morgan Healthcare Conference

ROCHESTER, Minn.--(BUSINESS WIRE)--Rion, a leader in regenerative medicine and exosome technology, today announced Dr. Atta Behfar, Co-Founder, will present at the 42nd Annual JP Morgan Healthcare Conference on Wednesday, January 10, 2024, at 02:00 PM. The presentation will showcase Rion's breakthrough developments in platelet-derived regenerative exosome technology and its significant impact across various regenerative medicine therapeutic areas.

“I am honored to be presenting at the JP Morgan Healthcare Conference, and to have the opportunity to share with other industry leaders our breakthrough regenerative exosome technology as we build a new therapeutic platform," said Dr. Atta Behfar, Co-Founder of Rion. "This platform allows us to highlight Rion's significant contributions to regenerative medicine and discuss our innovative regenerative exosome technology with a global audience.”

About Rion

Rion is a clinical-stage regenerative medicine company focused on developing innovative exosome therapeutics based on platelet-derived regenerative exosomes. Rion has built a proprietary exosome engineering and manufacturing platform for Platelet Exosome Product (PEPTM), an innovative and commercially viable biologic platform that optimizes the therapeutic power of exosomes for regenerative medicine. RION was established in 2017 and is headquartered in Rochester, Minnesota.

Contacts

Scott McCrea at mccrea@riontx.com

Industry:

Rion

Release Versions
English

Contacts

Scott McCrea at mccrea@riontx.com

More News From Rion

CORRECTING and REPLACING RION Launches RION Vet to Transform Animal Health with First-in-Class Biologic Therapeutic; Appoints Industry Leader Mark Herthel as CEO; Announces Series A Fulfillment

ROCHESTER, Minn.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: RION LAUNCHES RION VET TO TRANSFORM ANIMAL HEALTH WITH FIRST-IN-CLASS BIOLOGIC THERAPEUTIC; APPOINTS INDUSTRY LEADER MARK HERTHEL AS CEO; ANNOUNCES SERIES A FULFILLMENT RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of RION Vet, a veterinary biotechnology compa...

RION Engages Lonza to Scale Manufacturing Exosome Based Therapeutics

ROCHESTER, Minn. & BASEL, Switzerland--(BUSINESS WIRE)--RION, a commercial and clinical-stage regenerative medicine company pioneering platelet-derived exosomes for both human and animal health applications, has announced a collaboration with Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), to provide cGMP manufacturing and technical support for commercial scale production of its Purified Exosome Product™ (PEP™) drug substance for late phase clinic...

RION Launches INTENT Biologics to Develop Late-Stage Clinical Exosome-Based Therapies in Inflammation & Immunology; Appoints Biopharma Veteran Suneet Varma as CEO

ROCHESTER, Minn.--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of INTENT Biologics, a new independent biotechnology company focused exclusively on developing first-in-class exosome therapies for Inflammation & Immunology (I&I). INTENT Biologics launches with exclusive, perpetual worldwide rights to RION’s Purified Exosome Product (PEP™) biologic platform in I&I and will advance PE...
Back to Newsroom